Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 2 | 3 | 1998 | 0 | 1 | 1 | 2000 | 1 | 1 | 2 | 2001 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2006 | 1 | 0 | 1 | 2009 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2013 | 0 | 1 | 1 | 2014 | 0 | 3 | 3 | 2016 | 1 | 1 | 2 | 2017 | 0 | 1 | 1 | 2018 | 0 | 1 | 1 | 2019 | 0 | 2 | 2 | 2020 | 0 | 2 | 2 | 2021 | 1 | 3 | 4 | 2022 | 0 | 2 | 2 | 2024 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Phillips WJ, Watson AS, Camidge DR. The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments. J Thorac Oncol. 2025 May; 20(5):589-596.
-
D?hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, R?cher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, Ilaria R, Cobleigh MA, Juric D, Tkaczuk KHR, Elias A, Lee A, Dakhil S, Hamilton E, Soliman H, Peluso S. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024 Aug 30; 12(8).
-
Borgers JSW, Burgers FH, Terveer EM, van Leerdam ME, Korse CM, Kessels R, Flohil CC, Blank CU, Schumacher TN, van Dijk M, Henderickx JGE, Keller JJ, Verspaget HW, Kuijper EJ, Haanen JBAG. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial. BMC Cancer. 2022 Dec 30; 22(1):1366.
-
Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022 12 15; 28(24):5272-5279.
-
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
-
Camidge DR, Park H, Smoyer KE, Jacobs I, Lee LJ, Askerova Z, McGinnis J, Zakharia Y. Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. Future Oncol. 2021 Aug; 17(24):3271-3280.
-
Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, Libous J, Spector SA, Yogev R, Aziz M, Woods S, Wanionek K, Collins PL, Buchholz UJ. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children. Am J Respir Crit Care Med. 2021 03 01; 203(5):594-603.
-
Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
-
Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|